伊克力西斯 EXEL 深 滬
等待開盤 10-24 09:30:00 美东时间
38.05
+1.970
+5.46%
華盛通- 最 高38.33
- 今 開36.27
- 成交量 386.11万股
- 最 低 36.08
- 昨 收 36.08
- 總市值 102.35亿
- 52周最高 49.62
- 市盈率 靜 21.62
- 換手率 1.44%
- 52周最低 31.90
- 委 比 -68.90%
- 總股本 2.69亿
- 歷史最高 49.62
- 量 比 0.87
- 振 幅 6.24%
- 歷史最低 1.26
- 每 手 1
- 風險率 3.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
华尔街顶级分析师最新评级报告：高盛遭下调，Coinbase获初始覆盖
华尔街最受关注、且能影响市场走势的研究评级报告现已汇总于此。以下是由《The Fly》整理的今日投资者需重点关注的评级动态。 五家获上调评级的公司： 雷...
10-21 21:55
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development...
10-21 20:05
Leerink Partners Upgrades Exelixis to Outperform, Announces $48 Price Target
Leerink Partners analyst Christopher Liu upgrades Exelixis (NASDAQ:EXEL) from Market Perform to Outperform and announces $48 price target.
10-21 18:27
Exelixis Phase 3 STELLAR-303: Zanzalintinib Plus Atezolizumab Extends Survival To 10.9 Months In Metastatic Colorectal Cancer
– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly reduced the risk of death by 20% in the intention-to-treat population
10-20 14:45
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Adagene Inc. has amended its 2021 collaboration with Exelixis to develop an antibody-drug conjugate (ADC) targeting a solid tumor using its proprietary SAFEbody technology, enabling tumor-specific targeting with reduced side effects. Adagene is eligible for milestones and royalties, and its SAFEbody platform, designed to bind preferentially to tumor cells while masking in healthy tissues, has shown promise in clinical studies with its lead candid...
09-16 12:00
Peering Into Exelixis's Recent Short Interest
Exelixis's (NYSE:EXEL) short interest as a percent of float has risen 4.39% sin...
09-16 04:00
Exelixis shuttering Pennsylvania site, laying off 130 employees
Exelixis (NASDAQ:EXEL) is shutting down a facility in King of Prussia, Pa., to focus its operations at its headquarters in Alameda, Calif. As a result, 130 employees will be laid off, according to Fie...
09-04 22:19
